AbbVie Inc. Announces Quarterly Dividend of $1.64 per Share

AbbVie Inc. declares a quarterly dividend of $1.64 per share. The company specializes in therapeutic drug research and development, with a geographic sales distribution of 76.4% in the US, 2.6% in Germany, and smaller percentages in other countries.

AbbVie Inc. (NYSE: ABBV) has announced a quarterly cash dividend of $1.64 per share, payable on November 14, 2025, to shareholders of record as of October 15, 2025. This latest dividend increase underscores the company's commitment to shareholder value, as it has raised its dividend by 310% since its inception in 2013 [1].

AbbVie, a member of the S&P Dividend Aristocrats Index, has consistently increased its dividend for at least 25 consecutive years, reflecting its strong financial performance and stability. The company's mission is to discover and deliver innovative medicines that address serious health issues across key therapeutic areas, including immunology, oncology, neuroscience, and eye care, as well as its Allergan Aesthetics portfolio [1].

In addition to its dividend announcement, AbbVie has been actively expanding its product pipeline. Recently, the company agreed to pay up to $1.2 billion to acquire Gilgamesh's short-acting psychedelic bretisilocin, which is being explored for the treatment of psychiatric diseases, including major depressive disorder (MDD) [2]. This acquisition highlights AbbVie's growing interest in hallucinogenic drugs for mental health conditions.

AbbVie is also making progress with its lymphoma therapy, epcoritamab, in partnership with Genmab. New data from a mid-stage trial suggests that the bispecific antibody can be safely administered in an outpatient setting, potentially improving access to treatment for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) [3].

With a geographic sales distribution of 76.4% in the US, 2.6% in Germany, and smaller percentages in other countries, AbbVie continues to focus on its core markets while expanding its global footprint [1].

References:
[1] https://finance.yahoo.com/news/abbvie-declares-quarterly-dividend-130700697.html
[2] https://www.nature.com/articles/d41573-025-00149-0
[3] https://seekingalpha.com/news/4491809-abbvie-updates-data-genmab-partnered-lymphoma-drug